Potential of ErbB4 antibodies for cancer therapy

M Hollmén, K Elenius - Future Oncology, 2010 - Taylor & Francis
Antibodies targeting the extracellular domains of ErbB receptors have been extensively
studied for cancer drug development. This work has led to clinical approval of monoclonal …
被引用次数：48 相关文章

Potential of ErbB4 antibodies for cancer therapy

M Hollmén, K Elenius - Future oncology (London …, 2010 - pubmed.ncbi.nlm.nih.gov
Antibodies targeting the extracellular domains of ErbB receptors have been extensively
studied for cancer drug development. This work has led to clinical approval of monoclonal …

Potential of ErbB4 antibodies for cancer therapy

M Hollmen, K Elenius - Future Oncology, 2010 - go.gale.com
The ErbB/HER subfamily of receptor tyrosine kinases includes four members: EGFR (also
known as ErbB1 or HER1), ErbB2 (c-Neu, HER2), ErbB3 (HER3) and ErbB4 (HER4)[1, 2] …
[PDF] researchgate.net

[PDF][PDF] Potential of ErbB4 antibodies for cancer therapy

M Hollmén, K Elenius - researchgate.net
Antibodies targeting the extracellular domains of ErbB receptors have been extensively
studied for cancer drug development. This work has led to clinical approval of monoclonal …

Potential of ErbB4 antibodies for cancer therapy

M Hollmén, K Elenius - Future Oncology, 2010 - search.proquest.com
Antibodies targeting the extracellular domains of ErbB receptors have been extensively
studied for cancer drug development. This work has led to clinical approval of monoclonal …

Potential of ErbB4 antibodies for cancer therapy.

M Hollmén, K Elenius - Future Oncology (London, England), 2010 - europepmc.org
Antibodies targeting the extracellular domains of ErbB receptors have been extensively
studied for cancer drug development. This work has led to clinical approval of monoclonal …